FDA clears Bristol a number of myeloma remedy, marking debut of latest drug class

Adam Feuerstein is a senior author and biotech columnist, reporting on the crossroads of drug growth, enterprise, Wall Avenue, and biotechnology. He’s additionally a co-host of the weekly biotech podcast The Readout Loud and creator of the e-newsletter Adam’s Biotech Scorecard. You possibly can attain Adam on Sign at stataf.54.

The Meals and Drug Administration on Thursday authorised an oral remedy for superior a number of myeloma made by Bristol Myers Squibb, marking the debut of a brand new class of medication for the blood most cancers and the primary drug cleared by U.S. regulators utilizing a extra delicate measure of remission. 

The Bristol drug, iberdomide, might be bought beneath the model title Zenbexus. It is going to be utilized in mixture with two different medicine, Darzalex and dexamethasone, to deal with sufferers with a number of myeloma who’ve acquired no less than one prior line of remedy. 

“With the Zenbexus approval, Bristol is the primary firm to deliver a novel class of medicine to sufferers with a number of myeloma, opening venues for a lot of extra potential combos,” mentioned Cristian Massacesi, Bristol’s chief medical officer, in an interview with STAT forward of the approval announcement.